½ÃÀ庸°í¼­
»óǰÄÚµå
1441431

¼¼°è °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : ±Ô¸ð Á¶»ç ¹× ¿¹Ãø - ±â¼úº°, ¿ëµµº°, Áö¿ªº° ºÐ¼®(2023-2030³â)

Global Transdermal Drug Delivery Systems Market Size study & Forecast, by Technology by Application and Regional Analysis, 2023-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº 2022³â¿¡ ¾à 591¾ï 6,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, ¿¹Ãø ±â°£(2023³â-2030³â) µ¿¾È 11.90% ÀÌ»óÀÇ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

°æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛÀº ÇǺηκÎÅÍ ¾à¹°À» Åõ¿©ÇÏ´Â ÀåÄ¡À̸ç, ¾à¹°À» Àû¿ë ºÎÀ§·ÎºÎÅÍ Á÷Á¢ Ç÷·ù·Î Èí¼ö½Ãų ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ÀϹÝÀûÀ¸·Î ¾à¹°À» Æ÷ÇÔÇÏ´Â ÆÐÄ¡¿Í ±¹¼Ò Á¦ÇüÀ» »ç¿ëÇÏ¸ç ½Ã°£ÀÌ Áö³²¿¡ µû¶ó ¾à¹°ÀÌ Á¡Â÷ ¹æÃâµË´Ï´Ù. °æÇÇ Àü´ÞÀº °æ±¸ Åõ¿©¿¡ ºñÇØ ¾à¹°ÀÇ ¼­¹æ¼º, ȯÀÚÀÇ ÄÄÇöóÀ̾𽺠Çâ»ó, À§Àå°ü ºÐÇØÀÇ È¸ÇÇ, ºÎÀÛ¿ë À§ÇèÀÇ °¨¼Ò µî ¸î °¡Áö ÀåÁ¡ÀÌ ÀÖ½À´Ï´Ù. °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ´Â ¹è°æÀ¸·Î´Â ¸¸¼º ÁúȯÀÇ ÀÌȯÀ² Áõ°¡, ³ë³â Àα¸ Áõ°¡, °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ °³¹ß°ú »ç¿ëÀ» ÃËÁøÇÏ´Â Á¤ºÎÀÇ ±ä¹ÐÇÑ ³ë·Â µîÀÇ ¿äÀÎÀÌ ÀÖ½À´Ï´Ù.

½ÉÇ÷°ü Áúȯ, ´ç´¢º´, ÅëÁõ °ü·Ã Áúȯ°ú °°Àº ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡´Â °æÇÇ ÆÐÄ¡°¡ Á¦°øÇÒ ¼ö ÀÖ´Â Áö¼ÓÀûÀ̰í ÅëÁ¦µÈ ¾à¹°Àü´Þ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ÀÌ¿Í °°ÀÌ ¸¸¼ºÁúȯÀÇ À¯º´·ü »ó½ÂÀÌ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±¹Á¦ ´ç´¢º´ ¿¬ÇÕÀº 2021³â Àεµ ´ç´¢º´ ȯÀÚ ¼ö°¡ 7,419¸¸ 4,700¸íÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ ¼öÄ¡´Â 2030³â±îÁö 9,297¸¸ 3,700¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. °Ô´Ù°¡ ·Î¹öÆ® ¿ìµå Á¸½¼ Àç´ÜÀÇ º¸°í¿¡ µû¸£¸é ¹Ì±¹Àº 2020³â¿¡ 1¾ï 5,700¸¸ ¸íÀÇ ¸¸¼º Áúȯ ȯÀÚ°¡ ¹ß»ýÇß°í, 2030³â¿¡´Â 1¾ï 7,100¸¸¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ±¹Á¦¾Ï ¿¬±¸±â°ü(IARC)Àº 2021³â¿¡´Â 190¸¸¸íÀ̾ú´ø ½Å±Ô Áõ·Ê°¡ 2040³â¿¡´Â Àü ¼¼°è¿¡¼­ ¾à 2,750¸¸¸íÀÌ µÉ °ÍÀ¸·Î ÃßÁ¤Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿¬±¸°³¹ßÀÇ ÁøÀü°ú ÇコÄÉ¾î »ê¾÷¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡°¡ ½ÃÀå ¼ºÀå¿¡ »õ·Î¿î ±âȸ¸¦ °¡Á®¿À´Â ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ´ëü ½Ã½ºÅÛÀÇ °¡¿ë¼ºÀº 2023³â¿¡¼­ 2030³â »çÀÌÀÇ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÕ´Ï´Ù.

¼¼°è °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå Á¶»ç¿¡¼­ °í·ÁÇÑ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÔ´Ï´Ù. ºÏ¹Ì´Â 2022³â ÃÖ´ë ½ÃÀå Á¡À¯À²·Î ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù. ÀÌ Áö¿ª ½ÃÀå È®´ë´Â ÁַΠƯÇã ¸¸·áÀ¸·Î ½Å±Ô ±â¾÷ À¯ÀÔ¿¡ ÀÇÇØ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ÀÌÀü¿¡ ÆÈ¸®Áö ¾Ê¾Ò´ø ÀǾàǰÀÇ ÀçÆ÷Áö¼Å´×, ±âÁ¸ È­ÇÕ¹°ÀÇ ÀçÁ¦Á¦È­, ±âÁ¸ ¹× ½ÅÈï ½ÃÀå ÁøÃâ±â¾÷ ¸ðµÎ·ÎºÎÅÍÀÇ ¸¹Àº ÅõÀÚ°¡ ÀÌ Áö¿ª¿¡¼­ÀÇ Å« ½ÃÀå Á¸Àç¿¡ ÇöÀúÇÏ°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)·Î Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Ãß¼¼´Â °Ç°­ °ü¸® ÁöÃâ Áõ°¡¿Í °Ç°­ °ü¸® ÀÎÇÁ¶óÀÇ ½Å¼ÓÇÑ ÁøÈ­·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù. °Ô´Ù°¡ Áß±¹°ú Àεµ¿Í °°Àº ½ÅÈï°æÁ¦±¹¿¡¼­´Â ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÁÖ¸ñµµ°¡ ³ô¾ÆÁö°í ÀÎÁöµµ°¡ Çâ»óµÇ°í ÀÖ´Â °Íµµ È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

ÀÌ ¿¬±¸ÀÇ ¸ñÀûÀº ÃÖ±Ù ¸î ³â°£ÀÇ ´Ù¾çÇÑ ºÎ¹®¿Í ±¹°¡ ½ÃÀå ±Ô¸ð¸¦ ¹àÈ÷°í ¾ÕÀ¸·Î ¼ö³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼­´Â Á¶»ç ´ë»ó ±¹°¡¿¡¼­ »ê¾÷ÀÇ ÁúÀû ¹× ¾çÀû Ãø¸éÀ» ¸ðµÎ Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀΰú °úÁ¦ µî Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷ÀÇ °æÀï ±¸µµ¿Í Á¦Ç° Á¦°ø¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚ°¡ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¸¶ÀÌÅ©·Î½ÃÀåÀÇ ÀáÀçÀûÀÎ ±âȸµµ Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼¼°è °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§

  • Á¶»ç ¸ñÀû
  • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
    • ¾÷°èÀÇ ÁøÈ­
    • Á¶»ç ¹üÀ§
  • Á¶»ç ´ë»ó³âµµ
  • ȯÀ² º¯È¯À²

Á¦3Àå ¼¼°è °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå ¿ªÇÐ

  • °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀÇ ¿µÇ⠺м®(2020³â-2030³â)
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
      • ¸¸¼º Áúȯ Áõ°¡
      • °í·ÉÀÚ Àα¸ Áõ°¡
      • °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ °³¹ß°ú »ç¿ëÀ» ÃËÁøÇÏ´Â Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê
    • ½ÃÀåÀÇ °úÁ¦
      • °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ ³ôÀº ºñ¿ë
      • ±ÔÁ¦»óÀÇ °úÁ¦
    • ½ÃÀå ±âȸ
      • Áö¼ÓÀûÀÎ ¿¬±¸°³¹ß Ȱµ¿
      • ÇコÄÉ¾î »ê¾÷¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡

Á¦4Àå ¼¼°è °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå ºÐ¼®

  • Porter's Five Forces ¸ðµ¨
    • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
    • ±¸¸ÅÀÚÀÇ Çù»ó·Â
    • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
  • Porter's Five ForcesÀÇ ¿µÇ⠺м®
  • PEST ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ȯ°æ
    • ¹ý·ü
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • COVID-19ÀÇ ¿µÇ⠺м®
  • ÆÄ±«Àû µ¿Çâ
  • ¾÷°è Àü¹®°¡ÀÇ ½ÃÁ¡
  • ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð ¹× Á¦¾È

Á¦5Àå ¼¼°è °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : ±â¼úº°

  • ½ÃÀå ÇöȲ
  • ¼¼°è °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : ±â¼úº°, ½ÇÀû-°¡´É¼º ºÐ¼®
  • ¼¼°è °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå :±â¼úº°, ÃßÁ¤ ¹× ¿¹Ãø(2020³â-2030³â)
  • °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : ÇÏÀ§ ºÎ¹® ºÐ¼®
    • ÀÏ·ºÆ®·ÎÆ÷·¹À̼Ç
    • ¶óµð¿ÀÆÄ
    • ÀÌ¿ÂÅä Æ÷·¹½Ã½º
    • ¸¶ÀÌÅ©·ÎÆ÷·¹À̼Ç
    • ¿­
    • ¸ÞÄ¿´ÏÄà ¾î·¹ÀÌ
    • ÃÊÀ½ÆÄ
    • ±âŸ

Á¦6Àå ¼¼°è °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : ¿ëµµº°

  • ½ÃÀå ÇöȲ
  • ¼¼°è °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : ¿ëµµº°, ½ÇÀû-°¡´É¼º ºÐ¼®
  • ¼¼°è °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : ¿ëµµº°, ÃßÁ¤ ¹× ¿¹Ãø(2020³â-2030³â)
  • °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : ÇÏÀ§ ºÎ¹® ºÐ¼®
    • ÁßÃ߽Űæ°è
    • ÅëÁõ °ü¸®
    • ½ÉÇ÷°ü
    • È£¸£¸ó
    • ¸é¿ª
    • ´ë»ç
    • ¼ÒÈ­±â
    • °¨¿°Áõ
    • ¾Ï
    • ±âŸ

Á¦7Àå ¼¼°è °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå :Áö¿ªº° ºÐ¼®

  • ÁÖ¿ä±¹
  • ÁÖ¿ä ½ÅÈï±¹
  • °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : Áö¿ªº° ½ÃÀå ÇöȲ
  • ºÏ¹Ì
    • ¹Ì±¹
      • ±â¼úº° ÃßÁ¤ ¹× ¿¹Ãø(2020³â-2030³â)
      • ¿ëµµº° ÃßÁ¤ ¹× ¿¹Ãø(2020³â-2030³â)
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦8Àå °æÀï Á¤º¸

  • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Novartis AG
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫(µ¥ÀÌÅÍÀÇ À̿밡´É¼º¿¡ µû¸§)
      • Á¦Ç° °³¿ä
      • ÃÖ±Ù µ¿Çâ
    • Johnson & Johnson
    • Mylan Pharmaceuticals, Inc.
    • Boehringer Ingelheim GmbH
    • Hisamitsu Pharmaceutical co. Inc
    • 3M Company
    • Noven Pharmaceuticals, Inc.
    • 4P Therapeutics, LLC
    • Grunenthal GmbH
    • AbbVie Inc

Á¦9Àå Á¶»ç °úÁ¤

  • Á¶»ç °úÁ¤
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • °ËÁõ
    • ÃâÆÇ
  • Á¶»ç ¼Ó¼º
  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç
BJH 24.03.29

Global Transdermal Drug Delivery Systems Market is valued approximately at USD 59.16 billion in 2022 and is anticipated to grow with a growth rate of more than 11.90% over the forecast period 2023-2030. Transdermal drug delivery systems are a devices for administering medications through the skin, allowing drugs to be absorbed into the bloodstream directly from the application site. These systems typically involve the use of patches or topical formulations containing the drug, which gradually releases the medication over time. Transdermal delivery offers several advantages, including sustained release of drugs, improved patient compliance, avoidance of gastrointestinal degradation, and reduced risk of side effects compared to oral administration. The Transdermal Drug Delivery Systems market is expanding because of factors such as increasing incidence of chronic diseases, growing Geriatric Population and cohesive government initiatives promoting the development and use of transdermal drug delivery systems.

The increasing prevalence of chronic conditions such as cardiovascular diseases, diabetes, and pain-related disorders has boosted the demand for sustained and controlled drug delivery, which transdermal patches can provide. Thus, rising prevalence of chronic disease is driving the market growth. The International Diabetes Federation stated that India has an anticipated 74,194.7 thousand cases of diabetes in 2021, and that figure is expected to increase to 92,973.7 thousand cases by 2030. Furthermore, the Robert Wood Johnson Foundation reports that there were 157 million cases of chronic illness in the United States in 2020, with an expected rise to 171 million cases by 2030. Furthermore, International Agency for Research on Cancer (IARC), estimated that by year 2040 there would be around 27.5 million new cases across the globe from 1.9 million new cases in year 2021. In addition, Ongoing research and development activities and rising investment in healthcare industry are some factors creating new opportunities to the market growth. However, availability of alternatives systems stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Transdermal Drug Delivery Systems Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 with largest market share. The expansion of this region's market is primarily propelled by the expiration of patents, leading to an influx of new companies. Furthermore, the repositioning of previously unsuccessful drugs, the reformulation of existing compounds, and substantial investments from both established and emerging market participants have notably contributed to the significant market presence in this region. Asia Pacific is expected to grow significantly with fastest CAGR during the forecast period. This trend can be attributed to the increasing healthcare expenditure and the swift evolution of healthcare infrastructure. Furthermore, the expansion is fueled by the elevated focus on research and development and the rising awareness in emerging economies like China and India.

Major market player included in this report are:

  • Novartis AG
  • Johnson & Johnson
  • Mylan Pharmaceuticals, Inc.
  • Boehringer Ingelheim GmbH
  • Hisamitsu Pharmaceutical co. Inc
  • 3M Company
  • Noven Pharmaceuticals, Inc.
  • 4P Therapeutics, LLC
  • Grunenthal GmbH
  • AbbVie Inc

Recent Developments in the Market:

  • In September 2023, Satio achieved a significant milestone in its journey with funding from ARPA-H. This investment underscores the company's focus on advancing SatioRx, a pioneering transdermal drug delivery device tailored for home use and remote management.
  • In September 2022, Biomind Labs and Queen's University of Belfast obtained a controlled substances license, paving the way for the initiation of production for an innovative transdermal drug delivery system.

Global Transdermal Drug Delivery Systems Market Report Scope:

  • Historical Data - 2020 - 2021
  • Base Year for Estimation - 2022
  • Forecast period - 2023-2030
  • Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered - Technology, Application, Region
  • Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Technology:

  • Electroporation
  • Radio Frequency
  • Iontophoresis
  • Microporation
  • Thermal
  • Mechanical arrays
  • Ultrasound
  • Others

By Application:

  • CNS
  • Pain Management
  • Cardiovascular
  • Hormone
  • Immunological
  • Metabolic
  • Gastrointestinal
  • Infection
  • Cancer
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Transdermal Drug Delivery Systems Market, by region, 2020-2030 (USD Billion)
    • 1.2.2. Transdermal Drug Delivery Systems Market, by Technology, 2020-2030 (USD Billion)
    • 1.2.3. Transdermal Drug Delivery Systems Market, by Application, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Transdermal Drug Delivery Systems Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Transdermal Drug Delivery Systems Market Dynamics

  • 3.1. Transdermal Drug Delivery Systems Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing incidence of chronic diseases
      • 3.1.1.2. Growing geriatric population
      • 3.1.1.3. Government initiatives promoting the development and use of transdermal drug delivery systems
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of Transdermal Drug Delivery Systems
      • 3.1.2.2. Regulatory Challenges
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Ongoing research and development activities
      • 3.1.3.2. Rising investment in healthcare industry

Chapter 4. Global Transdermal Drug Delivery Systems Market: Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economic
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Transdermal Drug Delivery Systems Market, by Technology

  • 5.1. Market Snapshot
  • 5.2. Global Transdermal Drug Delivery Systems Market by Technology, Performance - Potential Analysis
  • 5.3. Global Transdermal Drug Delivery Systems Market Estimates & Forecasts by Technology 2020-2030 (USD Billion)
  • 5.4. Transdermal Drug Delivery Systems Market, Sub Segment Analysis
    • 5.4.1. Electroporation
    • 5.4.2. Radio Frequency
    • 5.4.3. Iontophoresis
    • 5.4.4. Microporation
    • 5.4.5. Thermal
    • 5.4.6. Mechanical arrays
    • 5.4.7. Ultrasound
    • 5.4.8. Others

Chapter 6. Global Transdermal Drug Delivery Systems Market, by Application

  • 6.1. Market Snapshot
  • 6.2. Global Transdermal Drug Delivery Systems Market by Application, Performance - Potential Analysis
  • 6.3. Global Transdermal Drug Delivery Systems Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
  • 6.4. Transdermal Drug Delivery Systems Market, Sub Segment Analysis
    • 6.4.1. CNS
    • 6.4.2. Pain Management
    • 6.4.3. Cardiovascular
    • 6.4.4. Hormone
    • 6.4.5. Immunological
    • 6.4.6. Metabolic
    • 6.4.7. Gastrointestinal
    • 6.4.8. Infection
    • 6.4.9. Cancer
    • 6.4.10. Others

Chapter 7. Global Transdermal Drug Delivery Systems Market, Regional Analysis

  • 7.1. Top Leading Countries
  • 7.2. Top Emerging Countries
  • 7.3. Transdermal Drug Delivery Systems Market, Regional Market Snapshot
  • 7.4. North America Transdermal Drug Delivery Systems Market
    • 7.4.1. U.S. Transdermal Drug Delivery Systems Market
      • 7.4.1.1. Technology breakdown estimates & forecasts, 2020-2030
      • 7.4.1.2. Application breakdown estimates & forecasts, 2020-2030
    • 7.4.2. Canada Transdermal Drug Delivery Systems Market
  • 7.5. Europe Transdermal Drug Delivery Systems Market Snapshot
    • 7.5.1. U.K. Transdermal Drug Delivery Systems Market
    • 7.5.2. Germany Transdermal Drug Delivery Systems Market
    • 7.5.3. France Transdermal Drug Delivery Systems Market
    • 7.5.4. Spain Transdermal Drug Delivery Systems Market
    • 7.5.5. Italy Transdermal Drug Delivery Systems Market
    • 7.5.6. Rest of Europe Transdermal Drug Delivery Systems Market
  • 7.6. Asia-Pacific Transdermal Drug Delivery Systems Market Snapshot
    • 7.6.1. China Transdermal Drug Delivery Systems Market
    • 7.6.2. India Transdermal Drug Delivery Systems Market
    • 7.6.3. Japan Transdermal Drug Delivery Systems Market
    • 7.6.4. Australia Transdermal Drug Delivery Systems Market
    • 7.6.5. South Korea Transdermal Drug Delivery Systems Market
    • 7.6.6. Rest of Asia Pacific Transdermal Drug Delivery Systems Market
  • 7.7. Latin America Transdermal Drug Delivery Systems Market Snapshot
    • 7.7.1. Brazil Transdermal Drug Delivery Systems Market
    • 7.7.2. Mexico Transdermal Drug Delivery Systems Market
  • 7.8. Middle East & Africa Transdermal Drug Delivery Systems Market
    • 7.8.1. Saudi Arabia Transdermal Drug Delivery Systems Market
    • 7.8.2. South Africa Transdermal Drug Delivery Systems Market
    • 7.8.3. Rest of Middle East & Africa Transdermal Drug Delivery Systems Market

Chapter 8. Competitive Intelligence

  • 8.1. Key Company SWOT Analysis
    • 8.1.1. Company 1
    • 8.1.2. Company 2
    • 8.1.3. Company 3
  • 8.2. Top Market Strategies
  • 8.3. Company Profiles
    • 8.3.1. Novartis AG
      • 8.3.1.1. Key Information
      • 8.3.1.2. Overview
      • 8.3.1.3. Financial (Subject to Data Availability)
      • 8.3.1.4. Product Summary
      • 8.3.1.5. Recent Developments
    • 8.3.2. Johnson & Johnson
    • 8.3.3. Mylan Pharmaceuticals, Inc.
    • 8.3.4. Boehringer Ingelheim GmbH
    • 8.3.5. Hisamitsu Pharmaceutical co. Inc
    • 8.3.6. 3M Company
    • 8.3.7. Noven Pharmaceuticals, Inc.
    • 8.3.8. 4P Therapeutics, LLC
    • 8.3.9. Grunenthal GmbH
    • 8.3.10. AbbVie Inc

Chapter 9. Research Process

  • 9.1. Research Process
    • 9.1.1. Data Mining
    • 9.1.2. Analysis
    • 9.1.3. Market Estimation
    • 9.1.4. Validation
    • 9.1.5. Publishing
  • 9.2. Research Attributes
  • 9.3. Research Assumption
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦